RESUMO
BACKGROUND: Allergic rhinitis (AR) and asthma may affect health-related quality of life. However, national estimates on the quality of life of patients with AR or asthma are lacking. OBJECTIVE: To provide estimates for utility scores and EuroQoL five-dimension (EQ-5D) visual analog scale (VAS) for patients with AR or asthma. METHODS: We conducted a cross-sectional study using direct patient data from the MASK-air app on European MASK-air users with self-reported AR or asthma. We used a multi-attribute instrument (EQ-5D) to measure quality of life (as utility scores and EQ-5D VAS values). Mean scores were calculated per country and disease control level using multilevel regression models with poststratification, accounting for age and sex biases. RESULTS: We assessed data from 7905 MASK-air users reporting a total of up to 82,737 days. For AR, utilities ranged from 0.86 to 0.99 for good control versus 0.72 to 0.85 for poor control; EQ-5D VAS levels ranged from 78.9 to 87.9 for good control versus 55.3 to 64.2 for poor control. For asthma, utilities ranged from 0.84 to 0.97 for good control versus 0.73 to 0.87 for poor control; EQ-5D VAS levels ranged from 68.4 to 81.5 for good control versus 51.4 to 64.2 for poor control. Poor disease control was associated with a mean loss of 0.14 utilities for both AR and asthma. For the same control levels, AR and asthma were associated with similar utilities and EQ-5D VAS levels. However, lower values were observed for asthma plus AR compared with AR alone. CONCLUSIONS: Poor AR or asthma control are associated with reduced quality of life. The estimates obtained from mobile health data may provide valuable insights for health technology assessment studies.
Assuntos
Asma , Qualidade de Vida , Rinite Alérgica , Humanos , Asma/epidemiologia , Masculino , Feminino , Adulto , Estudos Transversais , Pessoa de Meia-Idade , Rinite Alérgica/epidemiologia , Adulto Jovem , Adolescente , Inquéritos e Questionários , Idoso , Europa (Continente)/epidemiologiaRESUMO
Smart devices and Internet-based applications (apps) are largely used in allergic rhinitis and may help to address some unmet needs. However, these new tools need to first of all be tested for privacy rules, acceptability, usability, and cost-effectiveness. Second, they should be evaluated in the frame of the digital transformation of health, their impact on health care delivery, and health outcomes. This review (1) summarizes some existing mobile health apps for allergic rhinitis and reviews those in which testing has been published, (2) discusses apps that include risk factors of allergic rhinitis, (3) examines the impact of mobile health apps in phenotype discovery, (4) provides real-world evidence for care pathways, and finally (5) discusses mobile health tools enabling the digital transformation of health and care, empowering citizens, and building a healthier society.
Assuntos
Rinite Alérgica/diagnóstico , Smartphone , Telemedicina/estatística & dados numéricos , Atenção à Saúde , Europa (Continente)/epidemiologia , Humanos , Aplicativos Móveis , Fenótipo , Rinite Alérgica/epidemiologia , Rinite Alérgica/terapia , Fatores de RiscoRESUMO
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients.
Assuntos
Asma/terapia , Procedimentos Clínicos , Dessensibilização Imunológica , Rinite Alérgica/terapia , Alérgenos/administração & dosagem , Alérgenos/imunologia , Animais , Asma/epidemiologia , Asma/imunologia , Atitude do Pessoal de Saúde , Biomarcadores , Tomada de Decisão Clínica , Comorbidade , Efeitos Psicossociais da Doença , Análise Custo-Benefício , Dessensibilização Imunológica/efeitos adversos , Dessensibilização Imunológica/métodos , Gerenciamento Clínico , Suscetibilidade a Doenças , Humanos , Guias de Prática Clínica como Assunto , Medicina de Precisão/métodos , Rinite Alérgica/epidemiologia , Rinite Alérgica/imunologia , Resultado do TratamentoRESUMO
This review presents seven national asthma programmes to support the European Asthma Research and Innovation Partnership in developing strategies to reduce asthma mortality and morbidity across Europe. From published data it appears that in order to influence asthma care, national/regional asthma programmes are more effective than conventional treatment guidelines. An asthma programme should start with the universal commitments of stakeholders at all levels and the programme has to be endorsed by political and governmental bodies. When the national problems have been identified, the goals of the programme have to be clearly defined with measures to evaluate progress. An action plan has to be developed, including defined re-allocation of patients and existing resources, if necessary, between primary care and specialised healthcare units or hospital centres. Patients should be involved in guided self-management education and structured follow-up in relation to disease severity. The three evaluated programmes show that, thanks to rigorous efforts, it is possible to improve patients' quality of life and reduce hospitalisation, asthma mortality, sick leave and disability pensions. The direct and indirect costs, both for the individual patient and for society, can be significantly reduced. The results can form the basis for development of further programme activities in Europe.
Assuntos
Asma/terapia , Acessibilidade aos Serviços de Saúde , Programas Nacionais de Saúde , Regionalização da Saúde , Asma/diagnóstico , Asma/epidemiologia , Europa (Continente)/epidemiologia , Acessibilidade aos Serviços de Saúde/organização & administração , Acessibilidade aos Serviços de Saúde/normas , Humanos , Programas Nacionais de Saúde/organização & administração , Programas Nacionais de Saúde/normas , Guias de Prática Clínica como Assunto , Desenvolvimento de Programas , Melhoria de Qualidade , Indicadores de Qualidade em Assistência à Saúde , Regionalização da Saúde/organização & administração , Regionalização da Saúde/normas , Fatores de Tempo , Resultado do TratamentoRESUMO
The main objective of asthma treatment is to control symptoms of the disease; however, despite the availability of guidelines and many groups of medications, the degree of control of this condition is insufficient. In difficult-to-treat asthma, the optimal control cannot be achieved due to reasons independent of the disease. Factors worsening asthma control include: inadequate treatment plan (low therapy adherence and compliance), inappropriate inhalation technique, insufficient symptom control using the available classes of medications, incomplete response to treatment (non-responders, steroid-resistance), incorrect diagnosis of asthma or comorbidities, and environmental factors. In order to achieve the optimal asthma control, it is recommended to: take therapeutic decisions with the patient, assess the probability of non-compliance, perform detailed diagnostics and initiate treatment of concomitant diseases, carry out differential diagnosis of conditions mimicking asthma, educate the patient as to the inhalation technique and check it, eliminate unfavourable environmental factors, and modify current treatment. New treatment options for patients with asthma include: ultra-long-acting beta2-agonists, long-acting muscarine receptor antagonists (LAMA), monoclonal antibodies, and non-pharmacological interventions. The only LAMA approved for treatment of asthma is tiotropium bromide. The analyses performed demonstrated a high efficacy of tiotropium in terms of improved lung function parameters and prolonged time to the first asthma exacerbation. It is recommended as an add-on therapy at asthma treatment steps 4 and 5 according to GINA (Global Initiative for Asthma) 2014. The optimal asthma control is important from the medical as well as the economical point of view.
Assuntos
Antiasmáticos/administração & dosagem , Asma/tratamento farmacológico , Administração por Inalação , Asma/diagnóstico , Broncodilatadores/efeitos adversos , Broncodilatadores/uso terapêutico , Diagnóstico Diferencial , Custos de Cuidados de Saúde , Humanos , Cooperação do Paciente , Polônia , Brometo de Tiotrópio/administração & dosagemRESUMO
In this review, authors described epidemiology of asthma in regards to mortality and disability caused by the disease. In particular, long-time statistical analyses of asthma mortality in United States and Great Britain has been shown. Specific mortality factors between United States and Regional Health Authority of Lodz were compared. Economical costs of asthma management were studied, taking United States as an example. The review also focused on variety of preventive and counteraction programs, for example the national health program--'Prevention and treatment of asthma and allergic diseases'.
Assuntos
Asma/economia , Asma/epidemiologia , Custos de Cuidados de Saúde/estatística & dados numéricos , Asma/terapia , Efeitos Psicossociais da Doença , Análise Custo-Benefício , Saúde Global , Humanos , Avaliação de Resultados em Cuidados de Saúde , Educação de Pacientes como Assunto/economia , Polônia/epidemiologia , Reino Unido/epidemiologia , Estados Unidos/epidemiologiaRESUMO
Due to a rise in the number of cases of allergic disease and a need to increase financial resources for the diagnosis of these conditions, the possibility of reducing costs of skin pricks tests (SPT) was very welcome. In an attempt to reduce costs some practitioners use one lancet for several pricks in one patient. The purpose of this study was to determine whether this way of performing SPT influences the results. 52 subjects with (39) and without (13) atopy were tested with histamine, codeine and standard allergen extracts. SPT were applied to the volar surface of a randomly assigned forearm using two methods: one lancet-one prick on one forearm (single test method) and one lancet-multiple pricks ("multiple test" method) on the other. The false positive tests at the placebo site following allergen were recorded only in multiple test method, in 41 out of 72 pricks (p < 0.00001) when all reactions above baseline were considered and in 26 out of 72 (p = 0.00001) when a 3 mm cut-off was considered. The size of the false positive reaction depends on the intensity of the reaction to the preceding allergen (rang Spearman factor R = 0.706, p < 0.000001) and decreases in the second consecutive placebo test. Our data show that one lancet for multiple test method cannot be used to diagnose factors responsible for allergy, particularly in patients qualified for immunotherapy and in scientific studies. For financial reasons multiple test method can be used in screening and epidemiological studies where atopy is studied and there is no need to identify the specific allergen.